Bio-Path Holdings (BPTH)
(Delayed Data from NSDQ)
$2.23 USD
-0.08 (-3.46%)
Updated Jun 11, 2024 04:00 PM ET
After-Market: $2.26 +0.03 (1.35%) 7:56 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Bio-Path Holdings, Inc. [BPTH]
Reports for Purchase
Showing records 81 - 100 ( 119 total )
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2017 1Q Financial Results; Phase 2 AML Trial Interim Analysis On Track; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2017 1Q Financial Results; Phase 2 AML Trial Interim Analysis On Track; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Positive BP1002 Preclinical Data in NHL; Crucial AML Data in 2H 2017; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Positive BP1002 Preclinical Data in NHL; Crucial AML Data in 2H 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2016 Financial Results Reported; Phase 2 AML Combo Trial Enrolling; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2016 Financial Results Reported; Phase 2 AML Combo Trial Enrolling; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1001 CML Data Presented at ASH 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
BP1001 CML Data Presented at ASH 2016; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q16 Results; BP1001 CML Data at ASH 2016; Reiterate Buy and Adjusting Price Target to $4.50
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
3Q16 Results; BP1001 CML Data at ASH 2016; Reiterate Buy and Adjusting Price Target to $4.50
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 2 Efficacy Trial in AML; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 2 Efficacy Trial in AML; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q16 Results; BP1001 Phase 2 Efficacy Trial Underway; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
2Q16 Results; BP1001 Phase 2 Efficacy Trial Underway; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Financing Completed; Phase 2 Data Presented at ASCO; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Financing Completed; Phase 2 Data Presented at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
We are initiating coverage with a Buy rating and a 12-month price target of $5 per share.
Provider: Rodman & Renshaw, Co.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Improving Outcomes for Elderly AML Patients; Initiating at Buy with $5 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G
Company: Bio-Path Holdings, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: ZENG G